IntellectiveBio
智享生物
IntellectiveBio (智享生物) is a CDMO (contract development and manufacturing organization) focused on biopharmaceuticals, founded in April 2018 . The company raised over 500 million yuan in a Series C round in 2022, co-led by Gaorong Ventures and Qingsong Capital, with follow-on participation from Fuhui Ventures, CITIC Bank Investment Beijing, Founder Securities Investment, and Wenhua Haihui . Its CTO Wu Qiwei has appeared alongside Gaorong Ventures at industry panels on innovative drug R&D, clinical development, and manufacturing .
AI-generated — may contain errors, please verify.
Coverage
From Big Pharma to Biotech: Four Industry Leaders on How Innovative Drugs Can Balance Speed and Quality | Ronghui
Speed matters, but getting it right matters more.
Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
Multiple Innovative Companies Gain Global Recognition, Breakthroughs Achieved in Computational Biology, LiDAR, and Other Fields | Rongbao · July
Major events in July.
CDMO firm ZhiXiang Biologics raises over 500 million yuan in Series C funding to accelerate biopharma R&D for global clients
A one-stop CDMO platform for biologics R&D and manufacturing.
